OTCM
SONVY
Market cap18bUSD
Oct 08, Last price
61.81USD
1D
2.14%
1Q
23.02%
Jan 2017
158.06%
IPO
159.25%
Name
Sonova Holding AG
Chart & performance
P/E
35.45
P/S
4.23
EPS
7.25
Div yield, %
1.74%
Shrs. gr., 5y
-0.87%
Rev. gr., 5y
6.74%
Revenues
3.61b
-0.19%
Net income
431m
-20.33%
CFO
684m
-13.81%
Dividend
Jun 22, 20261.15978 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Stäfa, Switzerland, Sonova Holding AG is a leading provider of innovative hearing care solutions for both adults and children. The company's operations are divided into two primary segments: Hearing Instruments and Cochlear Implants. Sonova's extensive offerings include advanced wireless communication devices, rechargeable hearing aids, wireless headsets, speech-enhanced hearables, premium audiophile headphones, microphones, and wireless transmission systems, alongside comprehensive audiological care services. Its renowned hearing aid brands comprise Phonak, Unitron, and Hansaton, while Advanced Bionics is its flagship for cochlear implants. For consumer audio, Sonova offers products under the Sennheiser brand. The company delivers its audiological care through a vast network of around 3,600 clinics and stores operating under various regional names such as AudioNova, Audium, and Boots Hearingcare, among others. Additionally, its products are distributed via independent partners. Sonova boasts a significant international presence, serving markets across the United States, Europe, the Middle East, Africa, and the Asia Pacific. Founded in 1947, the company was formerly known as Phonak Holding AG before officially changing its name to Sonova Holding AG in August 2007.
Related entities
Subsidiaries (6)
Advanced Bionics AG
Sonova AG
Sonova Audiological Care Austria GmbH
SONOVA BELGIUM
SONOVA RETAIL BELGIUM
SONOVA AUDIOLOGICAL CARE FRANCE SAS
Key people
Ludger Althoff
Group Vice President - Operations, Member of the Management Board · since 2019
Lilika Beck
Group Vice President Consumer Hearing, Member of the Management Board · since 2024
Group Vice President Cochlear Implants, President of Advanced Bionics, Member of the Management Board · since 2019
Elodie Carr-Cingari
Chief Financial Officer, Member of the Management Board · since 2025
Martin Grieder
Group Vice President Hearing Instruments Marketing, Member of the Management Board · since 2016
Arnd Kaldowski
Chief Executive Officer, Member of the Management Board · since 2018
Katya Kruglova
Group Vice President Human Resources and Communications, Member of the Management Board · since 2023
Oliver Lux
Group Vice President Audiological Care, Member of the Management Board · since 2024
Alistair Simpson
Group Vice President Cochlear Implants and President of Advanced Bionics, Member of the Management Board · since 2024
General Vice President of Hearing Instruments, Member of the Management Board · since 2022
Gilbert Achermann
Non-Executive Independent Chairman of the Board · since 2025
Non-Executive Independent Chairman of the Board · since 2011
Non-Executive Independent Director · since 2021
Non-Executive Independent Director · since 2016
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2021
Non-Executive Independent Director · since 2022
Ronald Van Der Vis
Non-Executive Independent Director · since 2009
Non-Executive Independent Director · since 2020
Headquarters & legal address
Laubisrütistrasse 28
Stäfa, ZH 8712
CH
Stäfa, ZH 8712
CH
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||